Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01XMO
|
||||
Former ID |
DNC003683
|
||||
Drug Name |
LY-292728
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Terminated | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C34H29FO9
|
||||
Canonical SMILES |
CCC1=C(C=C(C(=C1)C2=CC=C(C=C2)F)O)OCCCOC3=C(C4=C(C=C3)C<br />(=O)C5=C(O4)C=CC(=C5)C(=O)O)CCC(=O)O
|
||||
InChI |
1S/C34H29FO9/c1-2-19-16-25(20-4-7-22(35)8-5-20)27(36)18-30(19)43-15-3-14-42-28-12-9-24-32(39)26-17-21(34(40)41)6-11-29(26)44-33(24)23(28)10-13-31(37)38/h4-9,11-12,16-18,36H,2-3,10,13-15H2,1H3,(H,37,38)(H,40,41)
|
||||
InChIKey |
DCTKEJXAVFAMFK-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Leukotriene B4 receptor 2 | Target Info | Inhibitor | [2] | |
Leukotriene B4 receptor 1 | Target Info | Inhibitor | [2] | ||
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
PANTHER Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | ||||
Reactome | Leukotriene receptors | ||||
G alpha (q) signalling eventsR-HSA-391906:Leukotriene receptors | |||||
G alpha (q) signalling events | |||||
WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, OtherWP80:Nucleotide GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Spinal Cord Injury | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007211) | ||||
REF 2 | J Med Chem. 1993 Nov 26;36(24):3982-4.Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.